< 生产厂家价格 >

5-(3-二甲氨基亚丙基)-二苯并[a,d]环庚三烯盐酸盐

用途

Cyclobenzaprine盐酸盐是骨骼肌松弛剂,对中枢神经有镇静活性。

点击显示

名称

[ CAS 号 ]:
6202-23-9

[ 中文名 ]:
盐酸环苯扎林

[ 英文名 ]:
Cyclobenzaprine hydrochloride

[中文别名 ]:

[英文别名 ]:

Cyclobenzaprine hydrochloride
MK 130 HCl
MFCD00079039
10,11d-Amitriptyline Hydrochloride
EINECS 228-264-4
Cyclobenzaprine (hydrochloride)

生物活性

[ 描述 ]:

Cyclobenzaprine盐酸盐是骨骼肌松弛剂,对中枢神经有镇静活性。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体

信号通路 >> 神经信号通路 >> 5-HT受体

研究领域 >> 神经疾病

[参考文献]

[1]. Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311(1): p. 29-35.

[2]. Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol, 2003. 458(1-2): p. 91-9.

[相关活性小分子]

物理化学性质

[ 沸点 ]:
405.9ºC at 760 mmHg

[ 熔点 ]:
216-218ºC

[ 分子式 ]:
C₂₀H₂₂ClN

[ 分子量 ]:
311.848

[ 闪点 ]:
9℃

[ 精确质量 ]:
311.144073

[ PSA ]:
3.24000

[ LogP ]:
5.35580

[ 外观性状 ]:
结晶固体

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
水溶性：完全溶解；易溶于：甲醇,乙醇；极微溶：氯仿

MSDS

详细MSDS(安全技术说明书)

毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HP0875000

CHEMICAL NAME :: 5H-Dibenzo(a,d)cycloheptene-delta(sup 5)-gamma-propylamine, N,N-dimethyl-, hydrochloride

CAS REGISTRY NUMBER :: 6202-23-9

LAST UPDATED :: 199504

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C20-H21-N.Cl-H

MOLECULAR WEIGHT :: 311.88

WISWESSER LINE NOTATION :: L C676 BHJ B3N1&1 &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 5714 ug/kg/2D-I

TOXIC EFFECTS :: Behavioral - wakefulness Behavioral - euphoria Behavioral - hallucinations, distorted perceptions

REFERENCE :: JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 54,39,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1 mg/kg/3D-I

TOXIC EFFECTS :: Behavioral - wakefulness Behavioral - euphoria Behavioral - hallucinations, distorted perceptions

REFERENCE :: JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 54,39,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 12 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Cardiac - pulse rate increase, without fall in BP

REFERENCE :: JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 20,281,1983

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 8400 ug/kg/2W-I

TOXIC EFFECTS :: Behavioral - general anesthetic

REFERENCE :: JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,151,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,87,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 36 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 144,481,1963 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5339 No. of Facilities: 100 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 656 (estimated) No. of Female Employees: 512 (estimated)

点击显示

安全信息

[ 符号 ]:

GHS02, GHS06, GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H225-H301 + H311 + H331-H370

[ 警示性声明 ]:
P210-P260-P280-P301 + P310-P311

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R20/21/22

[ 安全声明 (欧洲) ]:
36

[ 危险品运输编码 ]:
UN 2811 6.1/PG 3

[ WGK德国 ]:
3

[ RTECS号 ]:
HP0875000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1(b)

[ 海关编码 ]:
2942000000

海关

[ 海关编码 ]: 2921499090

[ 中文概述 ]:
2921499090 其他芳香单胺及衍生物及它们的盐. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

文献

Fast targeted analysis of 132 acidic and neutral drugs and poisons in whole blood using LC-MS/MS.

Forensic Sci. Int. 243 , 35-43, (2014)

The aim of this study was to develop an LC-MS/MS based screening technique that covers a broad range of acidic and neutral drugs and poisons by combining a small sample volume and efficient extraction...

Medications as a potential source of exposure to phthalates among women of childbearing age.

Reprod. Toxicol. 37 , 1-5, (2013)

To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception.Women enrolled in the Enviro...

Patient education and self-care for the management of jaw pain upon awakening: a randomized controlled clinical trial comparing the effectiveness of adding pharmacologic treatment with cyclobenzaprine or tizanidine.

J. Oral Facial Pain Headache 28(2) , 119-27, (2014)

To compare the effectiveness of adding cyclobenzaprine, tizanidine, or placebo to patient education and a self-care management program for patients with myofascial pain and specifically presenting wit...

更多文献